Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Cardiovascular Disease, Hypercholesterolemia, Obesity, Fatty Liver
Interventions: American Heart Association Diet, Reduced Fat Vegan Diet; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 9 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl tablets, and simvastatin tablets, simvastatin tablets and colesevelam HCl placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 14
States / cities: Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 11 more

Conditions: Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
Interventions: Etanercept; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Evinacumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Wilmington, Delaware • Boca Raton, Florida • Kansas City, Kansas + 3 more

Conditions: Diabetes, Hypertension, Hyperlipidemia, Heart Diseases, Depression, Psychoses
Interventions: pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Not listed
Enrollment: 3,048 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypercholesterolemia
Interventions: Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg, Placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 11
States / cities: Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more

Conditions: Hyperlipidemia
Interventions: Not listed
Lead sponsor: Scripps Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Type II Diabetes Mellitus, Mixed Dyslipidemia
Interventions: fenofibrate 160 mg and placebo, simvastatin 20 mg and placebo, fenofibrate 160 mg and simvastatin 20 mg; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 2
States / cities: Ogden, Utah • Salt Lake City, Utah

Conditions: Hypertriglyceridemia, Cardiovascular Diseases
Interventions: ISIS 678354, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more

Conditions: Hypercholesterolemia, Hyperlipidemia, Familial Combined
Interventions: colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more

Conditions: Hypercholesterolemia
Interventions: BiosLife Complete, Placebo; Dietary Supplement
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hyperlipidemia, HIV
Interventions: Pitavastatin, Darunavir, Ritonavir, Efavirenz; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Dyslipidaemias
Interventions: GW590735, fenofibrate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more

Conditions: Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
Interventions: MN-001; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Coronado, California • La Jolla, California • Seattle, Washington

Conditions: ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions: Inclisiran Sodium; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 141
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more

Conditions: Hypercholesterolemia, Hyperlipidemia, Vitamin Deficiency, Obesity
Interventions: Fortified eggs, Intermittent fasting, Non-egg supplemented, Usual care diet; Dietary Supplement · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypercholesterolemia
Interventions: MD-0727; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Walnut Creek, California + 17 more

Conditions: Hypertriglyceridemia
Interventions: 4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks; Drug
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hypertension, Hypercholesterolemia, Dementia Risk Factors
Interventions: Angiotensin Receptor Blockers (ARBs), Hydrophilic Statins or Non-Statin Alternative; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 50 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Familial Hypercholesterolemia
Interventions: LDL Apheresis; Procedure
Lead sponsor: Emory University; Other
Eligibility: 3 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Familial Chylomicronemia
Interventions: Plozasiran, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Boca Raton, Florida • Suwanee, Georgia • Indianapolis, Indiana + 5 more

Conditions: Metabolic Syndrome X, Atherosclerosis, Insulin Resistance, Hyperinsulinism, Glucose Metabolism Disorders, Metabolic Disease, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions: Prolonged sitting without exercise, Prolonged sitting with interval exercise; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 40 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more

Conditions: HIV Infections, Hyperlipidemia
Interventions: Pravastatin, Darunavir, Ritonavir, Washout; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Low Fat Vegan or American Heart Association Diets & Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Pharmacy Interventions to Improve Chronic Disease Medication Refill

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Comparison of LDL Particle Count With Other Available Lipid Tests

Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

The Effect of BiosLife on Serum Lipids

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

PROSPective Evaluation of Fortified Eggs Related to Improvement in The Biomarker Profile for Your Health

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

Vascular Intervention Strategies Trial for Alzheimer's

Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

The Effects of Interrupting Prolonged Sitting With Intermittent Exercise on Postprandial Lipemia

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin